Business Standard

US wants Covid-19 vaccine patent waiver to help world, not China biotech

Many companies and now some US officials fear the move would allow China to leapfrog years of research and erode the US advantage in biopharmaceuticals

Photo: Bloomberg
Premium

Photo: Bloomberg

Reuters
The Biden administration is examining ways to ensure that a waiver of Covid-19 vaccine patents to aid poor countries will not hand sensitive U.S. biopharmaceutical technology to China and Russia, responding to a chorus of concerns, U.S. and industry officials say.

President Joe Biden on Wednesday backed the U.S. entering negotiations at the World Trade Organization for the waiver of intellectual property rights as a means to boost vaccine supplies by allowing poorer countries to make their own.

So far, vaccines have gone overwhelmingly to richer nations, which scooped up contracts for them earlier this year. Covid-19 infection rates in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in